Watch Applovin, Fortinet, and Eli Lilly
Watch AppLovin (APP) shares today. APP stock gained nearly 12% to close at $437.34, after posting strong quarterly results.The advertising platform posted a 77.2% Y/Y increase in revenue, to $1.26 billion. It earned $2.28 a share. Q3 guidance pleased investors. Revenue will be $1.32 - $1.34 billion, while adjusted EBITDA margin will reach 81%. Advertising commerce advertisers plan to spend more in the current quarter.Fortinet (FTNT) is in trouble. The supplier of firewall hardware raised its billings outlook to $7.475 billion for Q3. However, this is below the market’s expectations. In the second quarter, it posted a 14% Y/Y rise in revenue, to $1.63 billion. Valuations are too high for the slowing growth rates.Eli Lilly (LLY), known for its blockbuster obesity drug, posted strong earnings and revenue (up by 37.7% Y/Y to $15.56 billion. The strong full-year guidance of $60 billion to $62 billion is also encouraging.Markets worried about Eli’s clinical data on its oral weight loss drug. Orforglipron, a once-daily GLP-1 receptor agonist, caused weight loss of 12.4% over 72% weeks at the highest dose. This met the goal in its Phase 3 study. Novo Nordisk’s (NVO) product offered up to a 13% weight loss in 12 weeks.Markets sent LLY stock down by 14.14% on Thursday. Shares are attractive at these levels, while NVO stock is an even better bargain.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


